SAN ANTONIO (EGMN) - The efficacy of the aromatase inhibitor anastrozole for prevention of breast cancer recurrence persists for years after treatment completion - but the side effects do not, according to the 100-month follow-up analysis of the landmark Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. "This is the first demonstration of a carryover effect for an aromatase inhibitor," Dr. John F. Forbes said in presenting the median 100-month ATAC data at the annual San Antonio Breast Cancer...